Latus Bio

Latus Bio is a private, pre-clinical stage biotech leveraging high-throughput screening and computational methods to discover novel AAV capsids for targeted gene therapy. The company's platform aims to enable tissue-specific delivery, dramatically lower therapeutic doses, reduce toxicity, and decrease manufacturing costs. Its initial pipeline targets severe monogenic CNS disorders, including Huntington's disease and CLN2 Batten disease, with programs advancing toward clinical development.

Proprietary platform using high-throughput in vivo screening and computational methods to discover and engineer novel AAV capsids for tissue-specific gene therapy delivery, aiming to drastically reduce required doses and improve safety.

Latus competes in the crowded next-generation AAV capsid engineering space, facing off against well-funded biotechs (e.g., Dyno Therapeutics, StrideBio, Affinia) and large pharma internal efforts. Its differentiation hinges on the potency and specificity claims of its capsids, particularly for CNS targets, and its focus on dramatic dose reduction.